Bussines Development


Autonomous University of Barcelona

Ability Pharmaceuticals has a research collaboration with Dr. José Miguel Lizcano's laboratory at the Department of Biochemisty, Faculty of Medicine of the Autonomous University of Barcelona, in Bellaterra.

Vall d'Hebron Institut d’Oncologia

Ability Pharmaceuticals Phase II clinical studies performed at the Department of Oncology at the Vall d'Hebron University Hospital. Dr. Ana Oaknin is the Principal Investigator.

SciClone Pharmaceuticals, Inc.

In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the NASDAQ US company SciClone Pharmaceuticals to develop and market the product in Greater China, with upfront and milestone payments over $ 20 M


Ability Pharmaceuticals has research collaborations with the Area of Molecular and Translational Oncology of the IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), associated with the Hospital Clinic de Barcelona and the University of Barcelona. The Area is led by Dr. Pere Gascon.

Hospital Clínic de Barcelona

Ability Pharmaceuticals conducted the Phase I/Ib clinical trials at the Medical Oncology Service and at the Clinical Institute of Hemato-Oncological Diseases y (ICMHO) of the Hospital Clinic de Barcelona. Dr. Laura Vidal was the Principal Investigator.

Institut Catala d'Oncologia

Ability Pharmaceuticals perform the phase II clinical studies in the Catalan Institute of Oncology (ICO) in the centers of L'Hospitalet, Girona and Badalona. Dr. Ernest Nadal, Dr. Joaquim Bosch and Dr. Teresa Moran are the principal investigators, respectively.

University of Girona

Ability Pharmaceuticals has a research collaboration with Dr. Teresa Puig's laboratory at the Department of Molecular Oncology, Faculty of Medicine of the University of Girona (Catalonia).

Universitat de Lleida

Ability Pharmaceuticals has a research collaboration with Dr. Xavier Matias-Guiu, head of pathological anatomy at Bellivtge Hosptial and Arnau de Vilanova Hospital and director of Biomedical Research Institute of Lleida (IRB). The collaboration also includes Dra. Nuria Eritja, head of the pathological laboratory and oncology group at IRB, and Dra. Eva Colàs, principal investigator currently in Vall d’Hebron Institut de Recerca (VHIR), Barcelona.

Vall d'Hebron Research Institute

Ability Pharmaceuticals has a research collaboration with Dr. Miguel Segura's laboratory of the Tranlational Research in Pediatric Carcer Group of the Vall d’Hebron Institut de Recerca (VHIR), Barcelona.


Medalchemy has developed the synthetic routes of the drug candidates being developed by Ability Pharmaceuticals and is proceeding to the escalation of their production.
Medalchemy is base at the Science Park of the University of Alicante/Alacant.




AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info


Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info


Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info


Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info


Ability Pharmaceuticals launches a new updated website with a fresh design + info


Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info


Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info


Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info


Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police